Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax

Biochemical and Biophysical Research Communications

Volumn 428, Issue 1, 2012, Pages 185-190

  Park, So Jung ^a,c   Park, Seong Ho ^b   Kim, Joo Oh ^a   Kim, Jung Ho ^a   Hwang, Jung Jin ^c,d   Jin, Dong Hoon ^c,d   Jeong, Seong Yun ^c,d   Lee, Seung Jin ^c,d   Kim, Jin Cheon ^c,d   Kim, InKi ^c   Cho, Dong Hyung ^a  

^a Kyung Hee University   (South Korea)

^b Hallym University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Asan Medical Center   (South Korea)

Author keywords

A549; Apoptosis; Carnitine; Resistance; Sensitization; TRAIL

Indexed keywords

CARNITINE; CASPASE; CASPASE INHIBITOR; LONG CHAIN FATTY ACID; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CARCINOMA; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; LUNG CANCER; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARNITINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

MUS;

EID: 84868339723     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.10.038     Document Type: Article

References (38)

1. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
2. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onsetprogression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
3. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9:459-470.
4. Bellail A.C., Qi L., Mulligan P., Chhabra V., Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 2009, 4:34-41.
5. Stegehuis J.H., de Wilt L.H., de Vries E.G., Groen H.J., de Jong S., Kruyt F.A. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist. Updates 2010, 13:2-15.
6. Van Geelen C.M., de Vries E.G., de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updates 2004, 7:345-358.
7. Abdulghani J., El-Deiry W.S. TRAIL receptor signaling and therapeutics. Exp. Opin. Therapeut. Targets 2010, 14:1091-1108.
8. Jin C.Y., Park C., Hwang H.J., Kim G.Y., Choi B.T., Kim W.J., Choi Y.H. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol. Nutr. Food Res. 2011, 55:300-309.
9. Lu M., Strohecker A., Chen F., Kwan T., Bosman J., Jordan V.C., Cryns V.L. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin. Cancer Res. 2008, 14:3168-3176.
10. Oh B., Park S., Pak J.H., Kim I. Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand. Biochem. Biophys. Res. Commun. 2012, 422:42-47.
11. Mingorance C., Rodriguez-Rodriguez R., Justo M.L., Herrera M.D., de Sotomayor M.A. Pharmacological effects and clinical applications of propionyl-l-carnitine. Nutr. Rev. 2011, 69:279-290.
12. Chang B., Nishikawa M., Nishiguchi S., Inoue M. l-Carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int. J. Cancer 2005, 113:719-729.
13. Ferrara F., Bertelli A., Falchi M. Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosis. Drugs Exp. Clin. Res. 2005, 31:109-114.
14. Choi S.Y., Kim M.J., Kang C.M., Bae S., Cho C.K., Soh J.W., Kim J.H., Kang S., Chung H.Y., Lee Y.S., Lee S.J. Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells. J. Biol. Chem. 2006, 281:7049-7059.
15. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
16. Roy M.J., Dionne S., Marx G., Qureshi I., Sarma D., Levy E., Seidman E.G. In vitro studies on the inhibition of colon cancer by butyrate and carnitine. Nutrition 2009, 11-12:1193-1201.
17. Vescovo G., Ravara B., Gobbo V., Sandri M., Angelini A., Della Barbera M., Dona M., Peluso G., Calvani M., Mosconi L., Dalla Libera L. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol. Cell Physiol. 2002, 283:C802-C810.
18. Oyanagi E., Yano H., Uchida M., Utsumi K., Sasaki J. Protective action of l-carnitine on cardiac mitochondrial function and structure against fatty acid stress. Biochem. Biophys. Res. Commun. 2011, 412:61-67.
19. Wenzel U., Nickel A., Daniel H. Increased carnitine-dependent fatty acid uptake into mitochondria of human colon cancer cells induces apoptosis. J. Nutr. 2005, 135:1510-1514.
20. Ferrara F., Bertelli A., Falchi M. Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosis. Drugs Exp. Clin. Res. 2005, 31:109-114.
21. Fan J.P., Kim H.S., Han G.D. Induction of apoptosis by l-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino Acids 2009, 36:365-372.
22. Kong J.Y., Rabkin S.W. Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am. J. Physiol. - Heart Circ. Physiol. 2002, 282:H717-725.
23. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
24. Li Y., Wang H., Wang Z., Makhija S., Buchsbaum D., LoBuglio A., Kimberly R., Zhou T. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res. 2006, 66:8508-8520.
25. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
26. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-5486.
27. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294.
28. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott F.L., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh J.M., Houghten R.A., Reed J.C. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5:25-35.
29. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D.J., Kaufmann S.H., Gores G.J. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004, 64:3517-3524.
30. Wirth T., Kühnel F., Fleischmann-Mundt B., Woller N., Djojosubroto M., Rudolph K.L., Manns M., Zender L., Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65:7393-7402.
31. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
32. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem. Pharmacol. 2003, 66:1537-1545.
33. Er E., Oliver L., Cartron P.F., Juin P., Manon S., Vallette F.M. Mitochondria as the target of the pro-apoptotic protein Bax. Biochim. Biophys. Acta 2006, 1757:1301-1311.
34. Shen Y., White E. P53-dependent apoptosis pathways. Adv. Cancer Res. 2001, 82:55-84.
35. Virmani A., Koverech A., Ali S.F., Binienda Z.K. Acetyl-l-carnitine modulates TP53 and IL10 Gene expression induced by 3-NPA evoked toxicity in PC12 cells. Curr. Neuropharmacol. 2011, 9:195-199.
36. Sayed-Ahmed M.M., Al-Shabanah O.A., Hafez M.M., Aleisa A.M., Al-Rejaie S.S. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur. J. Pharmacol. 2010, 640:143-149.
37. Cregan S.P., MacLaurin J.G., Craig C.G., Robertson G.S., Nicholson D.W., Park D.S., Slack R.S. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J. Neurosci. 1999, 19:7860-7869.
38. Peterson L.F., Mitrikeska E., Giannola D., Lui Y., Sun H., Bixby D., Malek S.N., Donato N.J., Wang S., Talpaz M. P53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia 2011, 25:761-769.